1,611
Views
4
CrossRef citations to date
0
Altmetric
Rare Diseases

Healthcare resource utilization among patients with cold agglutinin disease in Denmark

, , , , &
Pages 1829-1835 | Received 12 Mar 2021, Accepted 21 Jul 2021, Published online: 10 Aug 2021

References

  • Berentsen S, Ulvestad E, Langholm R, et al. Primary chronic cold agglutinin disease: a population based clinical study of 86 patients. Haematologica. 2006;91(4):460–466.
  • Bylsma LC, Ording AG, Rosenthal A, et al. Occurrence, thromboembolic risk, and mortality in danish patients with cold agglutinin disease. Blood Adv. 2019;3(20):2980–2985.
  • Berentsen S. Complement activation and inhibition in autoimmune hemolytic anemia: focus on cold agglutinin disease. Semin Hematol. 2018;55(3):141–149.
  • Rosse WF, Adams JP. The variability of hemolysis in the cold agglutinin syndrome. Blood. 1980;56(3):409–416.
  • Swiecicki PL, Hegerova LT, Gertz MA. Cold agglutinin disease. Blood. 2013;122(7):1114–1121.
  • Berentsen S. Cold agglutinin disease. Hematology Am Soc Hematol Educ Program. 2016;2016(1):226–231.
  • Berentsen S. How I manage patients with cold agglutinin disease. Br J Haematol. 2018;181(3):320–330.
  • Kamesaki T, Nishimura J, Wada H, et al. Demographic characteristics, thromboembolism risk, and treatment patterns for patients with cold agglutinin disease in Japan. Int J Hematol. 2020;112(3):307–315.
  • Broome C, Cunningham JM, Mullins M, et al. Incidence of thromboembolic events is increased in a retrospective analysis of a large cold agglutinin disease (CAD) cohort. Blood. 2017;130(Suppl_1):928–928.
  • Mullins M, Jiang X, Bylsma LC, et al. Cold agglutinin disease burden: a longitudinal analysis of anemia, medications, transfusions, and health care utilization. Blood Adv. 2017;1(13):839–848.
  • Su J, Bylsma LC, Jiang X, et al. Healthcare resource utilization among commercially insured patients with cold agglutinin disease in the United States. J Med Econ. 2020;23(8):902–907.
  • Schmidt M, Schmidt SAJ, Adelborg K, et al. The Danish health care system and epidemiological research: from health care contacts to database records. Clin Epidemiol. 2019;11:563–591.
  • Schmidt M, Schmidt SA, Sandegaard JL, et al. The Danish National Patient Registry: a review of content, data quality, and research potential. Clin Epidemiol. 2015;7:449–490.
  • Schmidt M, Pedersen L, Sorensen HT. The Danish Civil Registration System as a tool in epidemiology. Eur J Epidemiol. 2014;29(8):541–549.
  • Barcellini W, Zaninoni A, Fattizzo B, et al. Predictors of refractoriness to therapy and healthcare resource utilization in 378 patients with primary autoimmune hemolytic anemia from eight Italian reference centers. Am J Hematol. 2018;93(9):E243–E246.
  • Prabhu R, Bhaskaran R, Shenoy V, et al. Clinical characteristics and treatment outcomes of primary autoimmune hemolytic anemia: a single center study from South India. Blood Res. 2016;51(2):88–94.
  • Schöllkopf C, Kjeldsen L, Bjerrum OW, et al. Rituximab in chronic cold agglutinin disease: a prospective study of 20 patients. Leuk Lymphoma. 2006;47(2):253–260.
  • Berentsen S, Bø K, Shammas FV, et al. Chronic cold agglutinin disease of the “idiopathic” type is a premalignant or low-grade malignant lymphoproliferative disease. APMIS. 1997;105(5):354–362.
  • Berentsen S, Tjønnfjord GE, Shammas FV, et al. No response to cladribine in five patients with chronic cold agglutinin disease. Eur J Haematol. 2000;65(1):88–90.
  • Fløjstrup M, Bogh SB, Henriksen DP, et al. Increasing emergency hospital activity in Denmark, 2005-2016: a nationwide descriptive study. BMJ Open. 2020;10(2):e031409.